The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior endocrine therapy (ET)PALOMA-3
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Ribociclib
Letrozole
Letrozole + placebo
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-2
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Panitumumab
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
First-line treatment of patients with wild-type RAS mCRC PRIME
Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
Gastrointestinal Cancers
Colorectal Cancer
EGFR-expressing RAS-WT
CRYSTAL
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cetuximab
-
Best supportive care
Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
Gastrointestinal Cancers
Colorectal Cancer
KRAS-WT
CO.17
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Bevacizumab
Chemotherapy
Paclitaxel or topotecan or liposomal doxorubicin
In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agentsAURELIA
Gynaecological Malignancies
Ovarian Cancer
-
AURELIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Carboplatin gemcitabine
Locally advanced or metastatic NSCLC with EGFR activating mutationsOPTIMAL, CTONG-0802
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
OPTIMAL, CTONG-0802
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Platinum-based chemotherapy doublet
Locally advanced or metastatic NSCLC with EGFR activating mutationsEURTAC
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
EURTAC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Gefitinib
-
Carboplatin + paclitaxel
Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase.IPASS
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
IPASS
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s)LUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Osimertinib
-
Platinum/pemetrexed
As monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLCAURA3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
AURA3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Chemotherapy
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)PROFILE 1007
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1007
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Pemetrexed + cisplatin or carboplatin
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)PROFILE 1014
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1014
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pemetrexed
-
Placebo
As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pemetrexed
Cisplatin
Cisplatin + gemcitabine
In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Palliative care
Chemotherapy
Chemotherapy
First-line treatment stage IV NSCLC ECOG<2
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Nivo/Ipi (nivolumab and ipilimumab)
-
Ipilimumab
Ipilimumab in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older*CheckMate 067
Skin Cancers
Cutaneous Melanoma
-
CheckMate 067
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Nivolumab
-
Ipilimumab
Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older*CheckMate 067
Skin Cancers
Cutaneous Melanoma
-
CheckMate 067
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Ipilimumab
-
Glycoprotein 100 (GP100)
Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era)MDX010-20
Skin Cancers
Cutaneous Melanoma
HLA-A*0201
MDX010-20
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Vemurafenib
-
Dacarbazine
As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanomaBRIM-3
Skin Cancers
Cutaneous Melanoma
BRAF V600E
BRIM-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Vemurafenib
-
Dacarbazine
As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanomaBRIM-3
Skin Cancers
Cutaneous Melanoma
BRAF V600K
BRIM-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Trametinib
-
Dacarbazine or paclitaxel
As monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationMETRIC
Skin Cancers
Cutaneous Melanoma
BRAF V600
METRIC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Dabrafenib
-
Dacarbazine
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationBREAK-3
Skin Cancers
Cutaneous Melanoma
BRAF V600E
BREAK-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Nivolumab
-
Dacarbazine
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adultsCheckMate 066
Skin Cancers
Cutaneous Melanoma
-
CheckMate 066
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Ipilimumab
Dacarbazine
Dacarbazine + placebo
Advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (Basis of EMA and FDA approval of 1st-line ipilimumab monotherapy)CA184-024
Skin Cancers
Cutaneous Melanoma
-
CA184-024
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Radium-223
Best standard of care
Best standard of care + placebo
Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastasesALSYMPCA
Genitourinary Cancers
Prostate cancer
-
ALSYMPCA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
Prednisone
Prednisone + placebo
Indicated with prednisone or prednisolone for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based ChT regimenCOU-AA-301
Genitourinary Cancers
Prostate cancer
-
COU-AA-301
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Enzalutamide
-
Placebo
Adult men with mCRPC whose disease has progressed on or after docetaxel therapyAFFIRM
Genitourinary Cancers
Prostate cancer
-
AFFIRM
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Enzalutamide
-
Placebo
Castraction-refractory pre-docetaxel (early termination with crossover)PREVAIL
Genitourinary Cancers
Prostate cancer
-
PREVAIL
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Axitinib
-
Sorafenib
Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokineAXIS
Genitourinary Cancers
Renal cell cancer
-
AXIS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.